TrialBlood2023

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Sun Loo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.